ZHAOKE OPHTH-B(06622.HK): Presbyopia Innovative Drug YUVEZZI™ Approved for Urgent Clinical Import and Use at Boao Super Hospital
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution), its innovative drug for presbyopia, was approved by Hainan Provincial Medical Products Administration on 26 June 2026 for use as an urgently needed clinically imported drug at Boao Super Hospital. It marks the first innovative therapy approved in China for the treatment of presbyopia.
NewTimeSpace News: Zhaoke Ophthalmology Limited issued a voluntary announcement dated 7 July 2026, disclosing that YUVEZZI™, an novel ophthalmic drug for presbyopia, obtained approval from Hainan Provincial Medical Products Administration on 26 June 2026 to be used as an urgently needed clinically imported medicine at Boao Super Hospital.
YUVEZZI™ is a preservative-free, room-temperature-stable once-daily pupil-modulating eye drop formulation designed to restore near vision lost due to presbyopia. This fixed-dose combination of carbachol and brimonidine tartrate induces pupillary constriction to generate the pinhole effect, sharpening near and intermediate visual images.
The approval is granted under relevant State Council regulations governing the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Province, creating an early access pathway for Chinese patients to access innovative presbyopia therapies already launched globally. Zhaoke Ophthalmology licensed YUVEZZI™ from its U.S. partner Tenpoint Therapeutics Ltd., which secured FDA approval for the drug for presbyopia treatment in January 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- ZHAOKE OPHTH-B(06622.HK): Australia's TGA Accepts Registration Application for 0.02% Atropine Sulfate Eye Drops
- MicroPort MedBot (02252.HK) Toumo Global Commercial Orders Exceed 300 Units, H1 New Orders Surpass Full-Year 2025
- Zhaoke Ophthalmology-B (06622.HK): Expands Collaboration Network to Advance Commercialization of Presbyopia New Drug BRIMOCHOL™ PF in Asian Markets
